Skip to main content

Healthy Volunteers - Male and Female

1
Pipeline Programs
5
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Kaken Pharmaceutical
1 program
1
KP-001Phase 1
Clene
CleneSALT LAKE CITY, UT
1 program
CNM-Au8PHASE_11 trial
Active Trials
NCT02755870Completed86Est. Oct 2016
Parexel
ParexelMA - Boston
1 program
KP-001PHASE_11 trial
Active Trials
NCT06649942Completed40Est. Mar 2025
Orna Therapeutics
Orna TherapeuticsMA - Watertown
1 program
ORN252PHASE_11 trial
Active Trials
NCT07439796Recruiting20Est. Mar 2027
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
QLS7305 InjectionPHASE_11 trial
Active Trials
NCT07313150Not Yet Recruiting60Est. Dec 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Orna TherapeuticsORN252
Qilu PharmaceuticalQLS7305 Injection
ParexelKP-001
CleneCNM-Au8

Clinical Trials (4)

Total enrollment: 206 patients across 4 trials

A Study of ORN252 in Healthy Participants

Start: Mar 2026Est. completion: Mar 202720 patients
Phase 1Recruiting

A Phase I Trial of Subcutaneous QLS7305 in Healthy Adults

Start: Jan 2026Est. completion: Dec 202760 patients
Phase 1Not Yet Recruiting

A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults

Start: Oct 2024Est. completion: Mar 202540 patients
Phase 1Completed

A Phase I SAD and MAD Clinical Trial of CNM-Au8 in Healthy Male and Female Volunteers

Start: Apr 2015Est. completion: Oct 201686 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 206 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.